hsa-mir-922: Hsa-mir-922 is a microRNA that has been designed and synthesized by Shanghai GenePharma Co., Ltd. as a mimic and inhibitor [PMC8020205]. It has been found to regulate the expression and activity of the RUNX1 gene by interacting with other microRNAs, such as hsa-miR-603, hsa-miR-330-3p, hsa-miR-646, and hsa-mir-922 [PMC7886988]. These microRNAs can be sponged by multiple circular RNAs (circRNAs) [PMC7886988]. In the context of cancer-related target genes, hsa-mir-922 has been reported to regulate genes such as CASR, CDC25B, NFκB1, and SHOC2 [PMC8240180]. In other studies related to liver function and immune response modulation, hsa-mir-922 has been identified as one of the key microRNAs that negatively regulate downstream target genes [PMC4121398]. In the context of IgA nephropathy (IgAN), hsa-mir-922 is associated with upregulation of TGFBRAP1 gene expression [PMC9896983]. However, a correlation study between hsa-mir-922 and TGFBRAP1 in nephropathy has not yet been found [PMC9896983]. Overall, these studies highlight the regulatory role of hsa-mir-922 in various biological processes.